EGFR mutated NSCLC patiens with CNS metastases have poor prognosis. High-dose furmonertinib (160mg/day) have produced high CNS PFS and ORR in second-line for EGFR T790M mutated NSCLC. Whether EGFR mutated NSCLC with CNS metastases can benefit from first-line treatment of high-dose furmonertinib has not been reported. This study aims to investigate the efficacy and safety of high dose furmonertinib in first-line treatment of EGFR mutated NSCLC patiens.
Signed written informed consent before any study-related procedure.
Age ≥ 18 years.
ECOG PS of 0 to 1 at screening,and with no clinically significant deterioration in the previous 2 weeks.
Expected survival ≥12 weeks.
Small cell lung carcinoma;
History of hypersensitivity to active or inactive excipients of investigational agent with a similar chemical structure.
Confirmed EGFR 20 exon insertion mutations at any time after the initial diagnosis.
Any Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI).